How good is this, Imugene's "Principal activities" now extend down half a page!!!
"Principal activities -
The group is an Australian immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours.
Lead products under development by the group are HER-Vaxx, PD1-Vaxx (formerly KEY-Vaxx), CF33 and CF33CD19.
HER-Vaxx is a proprietary HER2-positive cancer vaccine that stimulates a polyclonal antibody response against the HER2/neu receptors which are prevalent in breast cancer and gastric cancer.
PD1-Vaxx a cancer vaccine which aims to induce the body to produce polyclonal antibodies that block PD-1 signalling, and thus produce an anticancer effect similar to Keytruda, Opdivo and the other immune checkpoint inhibiting monoclonal antibodies that are transforming treatment for a range of cancer indications.
CF33 is a is a combination of genomic sequences from multiple vaccinia virus strains to generate a new, safer and more potent virus.
CF33 CD19 directs chimeric antigen receptor (CAR) T cells therapies to target solid tumour."
Ann: Appendix 4E and Full Year Statutory Accounts, page-2
-
- There are more pages in this discussion • 68 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
